Levi & Korsinsky, LLP announces that it has commenced an investigation of Horizon Pharma plc ("Horizon Pharma" or the "Company") (NASDAQGS:HZNP) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On October 19, 2015, an article entitled "Drug Makers Sidestep Barriers on Pricing" was published on the New York Times website noting that certain drug manufacturers, including Horizon Pharma, have begun using specialty pharmacies "to circumvent efforts of insurers and pharmacists to switch patients to generic components, or even to the over-the-counter versions." According to the article, Horizon urges doctors to submit prescriptions to a mail-order specialty pharmacy affiliated with the drug company, rather than sending patients directly to the drugstore. The article further represents that Horizon Pharma's use of specialty pharmacies allows the Company to charge inflated prices for prescriptions. Following this news, shares of Horizon Pharma were down more than 20% on intraday trading on October 20, 2015. To obtain additional information about the investigation, go to: http://zlk.9nl.com/horizon-pharma or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.